Impel NeuroPharma, Inc. is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company is rapidly advancing a product pipeline that pairs its proprietary Precision Olfactory Delivery (POD®) system with well- established therapeutics, including TRUDHESA™ for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease. To learn more about Impel NeuroPharma, please visit our website at http://impelnp.com.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
SEATTLE, April 22, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (Impel), a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for patients suffering from...
Impel Neuropharma Announces Key Management Team Appointments as Company Advances Toward Commercialization in 2021
Mar 01, 2021
Leonard S. Paolillo Appointed as Chief Commercial Officer, Gerald F. Penn Appointed as Vice President, Market Access & Trade Significant Leadership Experience Continues Build Out of Impel’s Commercial Strategy, Infrastructure and Market Ac...
Impel Neuropharma Partners with Veeva Systems to Build Integrated, Digital-First Commercial Foundation
Feb 10, 2021
Impel adopting Veeva software, data, and consulting to accelerate pre-launch planning and digital-first commercial execution SEATTLE and PLEASANTON, CA — February 10, 2021 — Impel NeuroPharma and Veeva Systems (NYSE: VEEV) today announced a st...